Covered recipient · General Payments record
MICHAEL J WILLOZ
Physician Assistants & Advanced Practice Nursing Providers Nurse Practitioner
General Payments · PY2021–2024
$2,150.64
- Reported across 50 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $646.17 | 17 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| UCB, Inc. | $252.03 | 7 |
| Teva Pharmaceuticals USA, Inc. | $124.99 | 1 |
| Janssen Pharmaceuticals, Inc | $122.07 | 1 |
| PFIZER INC. | $71.36 | 4 |
| Acerta Pharma LLC | $31.14 | 2 |
| Neurelis, Inc. | $24.40 | 1 |
| Lundbeck LLC | $20.18 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (17)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $15.11 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104718419 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.03 | 07/24/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105222459 | CMS |
| Janssen Pharmaceuticals, Inc | $122.07 | 05/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1078034288 | CMS |
| Lundbeck LLC | $20.18 | 09/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146107902 | CMS |
| Neurelis, Inc. | $24.40 | 09/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145672402 | CMS |
| PFIZER INC. | $20.14 | 04/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131309092 | CMS |
| PFIZER INC. | $19.09 | 06/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131548915 | CMS |
| PFIZER INC. | $16.28 | 10/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131965001 | CMS |
| PFIZER INC. | $15.85 | 11/08/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1132129580 | CMS |
| Teva Pharmaceuticals USA, Inc. | $124.99 | 08/20/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151614668 | CMS |
| UCB, Inc. | $26.90 | 01/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104623 | CMS |
| UCB, Inc. | $119.94 | 02/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104625 | CMS |
| UCB, Inc. | $20.66 | 02/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104627 | CMS |
| UCB, Inc. | $26.87 | 04/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104629 | CMS |
| UCB, Inc. | $22.72 | 09/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104631 | CMS |
| UCB, Inc. | $9.85 | 10/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104633 | CMS |
| UCB, Inc. | $25.09 | 11/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1143104635 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2021, 2022, 2023, 2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.